{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:15:03Z","timestamp":1769822103838,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["JPMH23FC1013"],"award-info":[{"award-number":["JPMH23FC1013"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.seizure.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T16:20:50Z","timestamp":1728490850000},"page":"113-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Effectiveness of vigabatrin for infantile epileptic spasm syndrome categorized by etiologies"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9042-3602","authenticated-orcid":false,"given":"Hirokazu","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4844-6082","authenticated-orcid":false,"given":"Kenjiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikako","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuki","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7795-9139","authenticated-orcid":false,"given":"Reiko","family":"Koichihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiju","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9898-2230","authenticated-orcid":false,"given":"Hirofumi","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2024.10.003_bib0001","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1067\/S0022-3476(03)00323-8","article-title":"Long- term follow-up study of West syndrome: differences of outcome among symptomatic etiologies","volume":"143","author":"Hamano","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.seizure.2024.10.003_bib0002","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0387-7604(01)00269-8","article-title":"Long-term prognosis of patients with West syndrome in Japan: social aspects","volume":"23","author":"Kumagai","year":"2001","journal-title":"Brain Dev"},{"key":"10.1016\/j.seizure.2024.10.003_bib0003","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ridd.2019.03.010","article-title":"Neurodevelopmental outcomes of the West syndrome in pediatric patients: the first report from the Middle-East","volume":"89","author":"Nasiri","year":"2019","journal-title":"Res Dev Disabil"},{"key":"10.1016\/j.seizure.2024.10.003_bib0004","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(05)70199-X","article-title":"The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial","volume":"4","author":"Lux","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2024.10.003_bib0005","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.braindev.2005.07.002","article-title":"ACTH therapy for Taiwanese children with West syndrome \u2013 efficacy and impact on long-term prognosis","volume":"28","author":"Lin","year":"2006","journal-title":"Brain Dev"},{"key":"10.1016\/j.seizure.2024.10.003_bib0006","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/epi.12847","article-title":"Long-term outcome in children with infantile spasms treated with vigabatrin: a cohort of 180 patients","volume":"55","author":"Djuric","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2024.10.003_bib0007","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/088307389901400201","article-title":"Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review","volume":"14","author":"Hancock","year":"1999","journal-title":"J Child Neurol."},{"key":"10.1016\/j.seizure.2024.10.003_bib0008","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/epi.13671","article-title":"Instruction manual for the ILAE 2017 operational classification of seizure types","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2024.10.003_bib0009","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/epi.12951","article-title":"How should children with West syndrome be efficiently and accurately investigated? results from the national infantile spasms consortium","volume":"56","author":"Wirrell","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2024.10.003_bib0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.seizure.2020.12.008","article-title":"Comparison of adrenocorticotropic hormone efficacy between aetiologies of infantile spasms","volume":"85","author":"Daida","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2024.10.003_bib0011","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.seizure.2022.07.019","article-title":"Cohort study of infantile epileptic spasms syndrome: etiological analysis and treatment of corticosteroids","volume":"101","author":"Jiang","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2024.10.003_bib0012","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41436-019-0624-9","article-title":"Correction: sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria","volume":"22","author":"Nykamp","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.seizure.2024.10.003_bib0013","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ana.24594","article-title":"Response to treatment in a prospective national infantile spasms cohort","volume":"79","author":"Knupp","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2024.10.003_bib0014","first-page":"e2494","volume":"99","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2024.10.003_bib0015","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(04)17400-X","article-title":"The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial","volume":"364","author":"Lux","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2024.10.003_bib0016","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.seizure.2021.07.032","article-title":"What is the optimal duration for vigabatrin monotherapy in patients with infantile spasms: 6 months or longer?","volume":"91","author":"Desnous","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2024.10.003_bib0017","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/epi.16305","article-title":"The underlying etiology of infantile spasms (West syndrome): information from the international collaborative infantile spasms study (ICISS)","volume":"60","author":"Osborne","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2024.10.003_bib0018","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/0883073817712587","article-title":"Infantile Spasms and injuries of prematurity: short-term treatment-based response and long-term outcomes","volume":"32","author":"Wallace","year":"2017","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2024.10.003_bib0019","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.seizure.2023.05.012","article-title":"Long-term analysis of adrenocorticotropic hormone monotherapy for infantile epileptic spasms syndrome with periventricular leukomalacia","volume":"109","author":"Matsuura","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2024.10.003_bib0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jpeds.2006.12.004","article-title":"Developmental outcomes of cryptogenic West syndrome","volume":"150","author":"Hamano","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.seizure.2024.10.003_bib0021","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1528-1167.2011.03127.x","article-title":"The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study","volume":"52","author":"O'Callaghan","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2024.10.003_bib0022","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3348\/kjr.2017.18.4.729","article-title":"Value of repeat brain MRI in children with focal epilepsy and negative findings on","volume":"18","author":"Jeon","year":"2017","journal-title":"Initial MRI Korean J Radiol"},{"key":"10.1016\/j.seizure.2024.10.003_bib0023","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/0883073810365103","article-title":"Vigabatrin for the treatment of infantile spasms: final report of a randomized trial","volume":"25","author":"Elterman","year":"2010","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2024.10.003_bib0024","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/jcph.1309","article-title":"Proposition of a minimal effective dose of vigabatrin for the treatment of infantile spasms using pediatric and adult pharmacokinetic data","volume":"59","author":"Ounissi","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2024.10.003_bib0025","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1080\/14737175.2020.1840356","article-title":"Vigabatrin-related adverse events for the treatment of epileptic spasms: systematic review and meta-analysis","volume":"20","author":"Biswas","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.seizure.2024.10.003_bib0026","doi-asserted-by":"crossref","first-page":"187.e1","DOI":"10.1016\/j.jaapos.2022.05.001","article-title":"Ocular examinations, findings, and toxicity in children taking vigabatrin","volume":"26","author":"Schein","year":"2022","journal-title":"J AAPOS"},{"key":"10.1016\/j.seizure.2024.10.003_bib0027","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jpeds.2005.11.041","article-title":"Therapeutic efficacy and adverse effects of adrenocorticotropic hormone therapy in west syndrome: differences in dosage of adrenocorticotropic hormone, onset of age, and cause","volume":"148","author":"Hamano","year":"2006","journal-title":"J Pediatr"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131124002875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131124002875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:44:09Z","timestamp":1762033449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131124002875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":27,"alternative-id":["S1059131124002875"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2024.10.003","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of vigabatrin for infantile epileptic spasm syndrome categorized by etiologies","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}